2018

Conxi Lázaro, Juani Fernández and Alberto Villanueva receive an NF Research Initiative grant to test combination therapies in MPNST

Leave a Comment / Cancer, Hereditary cancer , Tumor and stromal chemoresistance  / By

The group of dr. Conxi Lázaro, principal investigator of the Hereditary cancer research group of the Oncobell program (IDIBELL) and head of the Molecular diagnostic Unit of the Hereditary cancer program (ICO), has been awarded one of five preclinical research grants that NF Research Initiative, an initiative linked to Boston Children Hospital, annually offers. This […]

Conxi Lázaro, Juani Fernández and Alberto Villanueva receive an NF Research Initiative grant to test combination therapies in MPNST Read More »

IDIBELL researchers successfully test a new combination therapy in sarcomas

Leave a Comment / Sarcoma / By

Researchers of the Sarcoma group of the Oncobell program – Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults. The results of the clinical trial, published in Targeted Oncology, represent a successful step in the translational research strategy

IDIBELL researchers successfully test a new combination therapy in sarcomas Read More »

IDIBELL-ICO researchers identify a new therapeutic target to fight metastasis in ovarian cancer

Leave a Comment / Cancer / By

Researchers of the Molecular Signaling in Cancer group of the Oncobell program (Bellvitge Biomedical Research Institute – IDIBELL) – proCURE Program (Catalan Institute of Oncology – ICO) have described a key cellular receptor in the processes of metastasis in ovarian cancer. The finding, published in Molecular Cancer Therapeutics, might lead to the use of inhibitors

IDIBELL-ICO researchers identify a new therapeutic target to fight metastasis in ovarian cancer Read More »

Scroll to Top